Galecto Inc. (GLTO) News
Filter GLTO News Items
GLTO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GLTO News Highlights
- For GLTO, its 30 day story count is now at 2.
- Over the past 7 days, the trend for GLTO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest GLTO News From Around the Web
Below are the latest news stories about GALECTO INC that investors may wish to consider to help them evaluate GLTO as an investment opportunity.
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter and year ended December 31, 2022. “2022 was an exciting year for us as we continued to progress our pipeline of small-molecule inhibitors of galectin-3 and LOXL2 and we now have three novel compounds in Phase 2 |
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare ConferenceBOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present and be available for 1x1 meetings at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually on March 13-15, 2023. Details for the event are as follows: Oppenheimer 33rd Annual Healthcare ConferenceDate:Monday, March |
Galecto to Participate in SVB Securities Global Biopharma ConferenceBOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming SVB Securities Global Biopharma Conference taking place on February 14-16, 2023. Details for the event are as follows: SVB Securities Global Biopharma ConferenceDate:Tuesday, February 14th, 2023Time:8:00 AM ESTWebcast |
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual MeetingIntermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients GB2064 is an oral inhibitor of the collagen cross-linking enzyme LOXL-2, which is linked to myelofibrosis BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibros |
Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowGalecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong BuyGalecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! |
Galecto Reports Third Quarter Operating and Financial ResultsBOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended September 30, 2022. “The recent release of positive results from two clinical trials, our Phase 1b/2a GULLIVER-2 trial in decompensated liver cirrhosis and our Phase 2a MYLOX-1 trial in myelofibrosis, has |
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis PatientsStatistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and |